NEW YORK (GenomeWeb News) – Alnylam Pharmaceuticals has granted Quark Biotech licenses to discover, develop, and commercialize RNAi therapeutics targeting the RTP801 gene for age-related macular degeneration, the companies said yesterday.
 
Simultaneously, Quark has agreed to withdraw its support of opposition to the Kreutzer-Limmer patent estate currently granted in Europe.
 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Researchers have sequenced the northern white rhinoceros to gauge whether it could be brought back from the edge of extinction, the New York Times reports.

Tufts University researchers found a role for miRNA in transmitting stress between generations, the Economist reports.

Bavaria expands its forensic genetic analyses to include DNA phenotyping, raising discrimination concerns.

In Science this week: gut microbiome influences liver cancer growth, spread; and more.

Jun
19
Sponsored by
Advanced Cell Diagnostics

This webinar will provide evidence for the use of RNA in situ hybridization (RNA ISH) as a replacement for immunohistochemistry (IHC) in cancer research and diagnostic applications.